Table IV.
Results of selected studiesk.
| Study, year | Methods for evaluation of the symptoms | Suprapubic pain | Dysuria | Frequent voiding | Urgency | Hematuria | Overall symptoms evaluation | (Refs.) |
|---|---|---|---|---|---|---|---|---|
| Porru et al, 2014 | VAS | (6) | ||||||
| Before D-mannose | 4.1 (1.1)c | 7.1 (1.1)b | 4.6 (1.1) | |||||
| After D-mannose | 2.2 (0.5)a | 4.7 (1.0)a | 2.6 (0.7)a | |||||
| Vicariotto, 2014 | UTI-SAQ | (7) | ||||||
| Baseline | 1.39 | 2.03 | 2.18 | 2.15 | 0.61 | |||
| Day 30 | 0.97a | 1.36a | 1.70a | 1.64a | 0.58 | |||
| Domenici et alb,h, 2016 | UTI-SAQ | (8) | ||||||
| Baseline | 1.47 (0.95) | 1.60 (±1.00) | 2.16 (1.52) | 1.73 (0.92) | 0.34 (0.90) | |||
| Day 15 | 0.15 (0.36)a | 0.31 (0.47)a | 0.60 (0.63)a | 0.23 (0.43)a | 0.10 (0.45) | |||
| Marchiori and Zanello, 2017 | VRS | (9) | ||||||
| Cases | ||||||||
| Baseline | 32.5% (13/40)e,j | 62.5% (25/40) | 37.5% (15/40)f | |||||
| 2 months | 25% (10/40) | 5% (2/40) | 0% (0/40) | |||||
| Control group | ||||||||
| Baseline | 50% (10/20) | 35% (7/20) | 20% (4/20) | |||||
| 2 months | 45% (9/20) | 25% (5/20) | 5% (1/20) | |||||
| Del Popolo and Nelli, 2020 | VAS | (10) | ||||||
| Neurogenic bladder group | ||||||||
| Baseline | 14.0 (2.6)d | 8.07 (1.70)h | ||||||
| 2 weeks | 6.9 (1.3)a | 4.74 (2.07)a | ||||||
| Non neurogenic bladder group | ||||||||
| Baseline | 15(3)b | 7.21 (1.9) | ||||||
| 2 weeks | 8(3)a | 3.74 (3.12)a | ||||||
| Pugliese et al, 2020 | ACSS | (11) | ||||||
| Baseline | 11.5i (95% CI, 10.5-12.6) | |||||||
| 15 days | 4.9a (95% CI 4.0-5.9) | |||||||
| Rădulescu et all, 2020 | 3 degrees | (12) | ||||||
| Cases | questionnaire | |||||||
| Baseline | 72.9 (35/48)g,j | 60.4 (29/48) | 85.4 (41/48) | 89.6% (43/48) | 10.4% (5/48) | |||
| 7 days | 2.1 (1/48) | 0% (0/48) | 2.1% (1/48) | 0% (0/48) | 0% (0/48) | |||
| Control group | ||||||||
| Baseline | 86.7% (39/45) | 55.6% (25/45) | 82.2% (37/45) | 80% (36/45) | 22.2% (10/45) | |||
| 7 days | 2.2% (1/45) | 6.7% (3/45) | 8.9% (4/45) | 4.4% (2/45) | 0% (0/45) |
aP<0.05.
bDomenici et al also reported a statistically significant reduction of back pain and nycturia.
cPain not otherwise specified.
dNumber of voiding events/24 h.
eBladder and urethral pain.
fImperious urination.
gVesical tenesmus.
hEvaluation of all symptoms.
iTypical symptoms score.
jModerate or severe/total subjects.
kUnless otherwise specified, data are presented as mean and standard deviation.
lRădulescu et al also reported a decrease of lumbar pain and hypogastric pain. UTI-SAQ, UTI-Symptoms Assessment Questionnaire; VRS, verbal rating scale; ACSS, Acute Cystitis Symptoms Score; CI, confidence interval; VAS, visual analogue scale.